Indaptus Therapeutics Inc
INDP
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.08M
Close$
$8.81
298.5% upside
Current Fair Value
298.5% upsideUndervalued by 298.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.08 Million |
|---|---|
| Enterprise Value | $1.58 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-21.58 |
| Beta | 1.39 |
| Outstanding Shares | 2,167,324 |
Return
| Return on Equity | -1511.20% |
|---|---|
| Return on Assets | -864.69% |
| Return on Invested Capital | -1484.09% |
Valuation & Multiples
| P/E Ratio | -0.2 |
|---|---|
| PEG | 0.46 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.09 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-1.87
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 17, 2026
EPS Estimate
$-1.57
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.26%▲ 3.26% |
|---|---|
| Total Invested | $128,549 |
| Investors Holding | 6▲ 6.00% |
ESG Score
No data
About Indaptus Therapeutics Inc
40 employees
CEO: Jeffrey Meckler Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve ...